Potential Angiotensin Converting Enzyme Inhibitors from Moringa oleifera

Author(s): Huma Khan, Varun Jaiswal, Saurabh Kulshreshtha, Azhar Khan*.

Journal Name: Recent Patents on Biotechnology

Volume 13 , Issue 3 , 2019

Become EABM
Become Reviewer

Graphical Abstract:


Background: Hypertension is the chronic medical condition and it affected billions of people worldwide. Natural medicines are the main alternatives to treatment for a majority of people suffering from hypertension. Niazicin-A, Niazimin-A, and Niaziminin-B compounds from Moringa oleifera ethanolic leave extract were reported to have potent antihypertensive activity.

Objective: These compounds were targeted with Angiotensin-converting enzyme [ACE] which is one of the main regulatory enzymes of the renin-angiotensin system.

Methods: Protein-ligand docking of these compounds with [ACE] [both domain N and C] was conceded out through Autodock vina and visualization was done by chimera. Pharmacokinetics study of these compounds was predicted by ADME-Toxicity Prediction.

Results: Niazicin-A, Niazimin-A, and Niaziminin-B showed high binding affinity with ACE and partially blocked the active sites of the enzyme. Niazicin-A, Niazimin-A and Niaziminin-B showed the estimated free binding energy of -7.6kcal/mol kcal/mol, -8.8kcal/mol and -8.0kcal/mol respectively with C-domain of ACE and -7.9kcal/mol, -8.5kcal/mol and -7.7kcal/mol respectively with N-domain of ACE. The compounds showed better binding energy with angiotensinconverting enzyme in comparison to Captopril -5.5kcal/mol and -5.6kcal/mol and Enalapril [standard] -8.4kcal/mol and -7.5kcal/mol with C and N domain, respectively.

Conclusion: Computationally, the selected bioactive molecules have shown better binding energy to known standard drugs which have been already known for inhibition of ACE and can further act as a pharmacophore for in vitro and in vivo studies in the development of alternative medicine.

Keywords: Docking, hypertension, autodock vina, angiotensin converting enzyme, Niazicin-A, Niazimin-A, Niaziminin-B, captopril, and Moringa oleifera.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2019
Page: [239 - 248]
Pages: 10
DOI: 10.2174/1872208313666190211114229
Price: $58

Article Metrics

PDF: 26